United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Core Insights - Biomerica, Inc. has received approval from the UAE Ministry of Health and Prevention for its Fortel Kidney Disease (Microalbumin) Test, enabling its sale in a region with a high prevalence of chronic kidney disease (CKD) [1][8] - The Fortel Kidney Disease Test is a rapid diagnostic tool that provides results in 10 minutes using a urine sample, allowing for early detection of kidney disease [2][8] - CKD is a significant global public health issue, with over 80% of at-risk patients undiagnosed, and is projected to be the 5th leading cause of years of life lost by 2040 [2][8] Company Overview - Biomerica is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products for point-of-care and clinical laboratory use [7] - The company aims to enhance health and well-being while reducing healthcare costs, with a particular focus on gastrointestinal and inflammatory diseases [7] Market Context - In the UAE, diabetes and hypertension are major risk factors for CKD, with over 12% of adults living with diabetes and 29% to 35% estimated to have hypertension [4] - CKD is often asymptomatic until advanced stages, making early detection crucial for effective intervention [4][5] Strategic Initiatives - The approval of the Fortel Kidney Disease Test supports Biomerica's mission to provide life-saving diagnostic tools in high-need areas, particularly in the Middle East [5][6] - The company has established partnerships with leading distributors and healthcare providers in the UAE to ensure the test's availability across the country [5]